Apogee Q3 net loss $65M; APG333 half-life ~55 days supports quarterly dosing; cash $913M, runway into 2H 2028

Apogee Therapeutics, Inc.

Q3 2025 net loss $65.0M vs $49.0M YoY; cash and securities $588.9M pre-offering, $913M pro forma post-$345M equity offering.
APG333 Phase 1 data: half-life ~55 days, biomarker suppression for 6 months, well tolerated up to 1000 mg; supports quarterly or better dosing for APG273 co-formulation.
APG777 readouts accelerated: Phase 1b asthma data Q1 2026; APEX Part A 52-week data Q1 2026; APEX Part B 16-week data Q2 2026; Phase 3 start 2H 2026.
APG279 (APG777+APG990) head-to-head vs DUPIXENT in AD interim readout expected 2H 2026.
Cash runway extended into 2H 2028 through Phase 3 topline data for APG777.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.